-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50

Benzinga·12/16/2025 17:28:56
语音播报
Stifel analyst James Condulis maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $44 to $50.